Skip to main content
Premium Trial:

Request an Annual Quote

Rob Thomas and Metin Colpan

Premium

Benitec said last week that it has appointed as non-executive director and deputy chairman of its board Rob Thomas.

Thomas, said Benitec, is currently chairman of Citigroup Global Corporate & Investment Bank, Australia and New Zealand. He previously served as managing director of County NatWest Securities Australia, and became CEO, Australia and New Zealand of Salomon Smith Barney when it acquired CNWSAL.

“Having someone of [Thomas’] stature as deputy chairman brings greater independence, strength, and credibility to the board,” Benitec chairman and CEO John McKinley said in a statement. “His particular expertise in global capital markets will be of tremendous assistance to Benitec as it expands first into the USA and then on a worldwide basis.”


MorphoSys said this week that its shareholders have confirmed the appointment of Metin Colpan to the company’s supervisory board.

Colpin was most recently co-founder, CEO, and managing director of Qiagen, and replaces Jorg Reinhardt of Novartis Pharma at MorphoSys.

“Colpan’s experience in building Qiagen into one of the world’s leading biotechnology companies will be invaluable for MorphoSys to foster our new business initiative in the reagent field, Antibodies by Design,” MorphoSys CEO Simon Moroney said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.